TORONTO, Sept. 12 /CNW/ - Bradmer Pharmaceuticals Inc., a
biopharmaceutical company dedicated to the development and commercialization
of cancer therapies, today announced that the Board of Directors has appointed
Paul J. Van Damme, MBA, CA, to the position of Chief Financial Officer
effective September 12, 2007. Mr. Brian Brohman will continue to serve in a
leadership position as Chief Business Officer of the Company.
"Mr. Van Damme brings significant expertise in corporate finance,
corporate governance and compliance, and investor relations to the management
team at Bradmer," said Dr. Alan M. Ezrin, Chief Executive Officer of Bradmer.
"With an extensive background in the life science sector for public companies
listed in both Canada and the United States, Paul adds tremendous depth to our
team and will play a key role in our future growth."
Mr. Van Damme has previously held the senior finance position on the
management team of three publicly traded life science companies, Vasogen Inc.,
Lorus Therapeutics Inc. and NPS Pharmaceuticals, Inc. (formerly Allelix
Biopharmaceuticals Inc.). Mr. Van Damme currently serves on the Board of
Directors and the Audit Committee of the Ontario Genomics Institute. Earlier
in his career, Mr. Van Damme was an Audit Manager for PricewaterhouseCoopers.
He is a member of a number of professional associations including the
Association for Investment Management and Research and Financial Executives
International. He received his Master in Business Administration from the
Rotman School of Management at the University of Toronto.
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of new and innovative cancer therapies.
Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University
Medical Center as a proprietary therapy for a particularly aggressive form of
brain cancer, glioblastoma multiforme. To date, over US$60 million in grants
and related support has driven research and development of the licensed
treatment, which has been delivered to over 200 patients with promising
results and has completed Phase II clinical trials at Duke University. Bradmer
is currently in the process of organizing a prospective multi-center clinical
trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status
by both the U.S. Food and Drug Administration and the European Medicines
Bradmer Pharmaceuticals Inc.'s common shares have not been registered
under the Securities Act of 1933, as amended (the "Securities Act") or any
state regulatory agency in the United States. The resale or transfer by a U.S.
investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to
the requirements of Rule 904 of Regulation S of the Securities Act or such
other applicable exemption thereunder, and other applicable state securities
Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.
For further information:
For further information: Bradmer Pharmaceuticals Inc., Mr. Brian
Brohman, Chief Business Officer, Phone: (416) 361-6058 (Ext. 804), E-mail:
email@example.com; Internet: www.bradmerpharma.com; Investor
Relations, Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext.
238), Fax: (416) 815-0080, E-mail: firstname.lastname@example.org